News | Ablation Systems | May 14, 2019

New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias

Collaboration between international societies provides first updated recommendations since 2009 for the care of patients with ventricular arrhythmias

New Global Consensus Statement Addresses Catheter Ablation of Ventricular Arrhythmias

May 14, 2019 — The Heart Rhythm Society (HRS) in partnership with three other professional societies issued an international consensus statement reflecting a worldwide updated review of the indications, techniques and outcomes of catheter ablation of ventricular arrhythmias (VAs). The expert consensus statement was presented at Heart Rhythm 2019, the HRS’s 40th Annual Scientific Sessions, May 8-11 in San Francisco.

VAs are abnormal rapid heart rhythms that originate in the lower chambers of the heart, known as the ventricles, and are sometimes associated with heart attacks or scarring of the heart muscle. VAs come in a variety of forms, from single premature ventricular complexes (PVCs) to sustained ventricular tachycardia and fibrillation, and are an important cause of morbidity and mortality. Today, catheter ablation has become a more common treatment option for patients whose condition cannot be controlled by medical therapy. In an effort to better understand, diagnose and treat VAs, the field of catheter ablation has progressed rapidly with the development of new methods and tools, and with the publication of clinical trial outcomes and key learnings.

The EHRA/HRS Expert Consensus on Catheter Ablation of Ventricular Arrhythmias, first issued in 2009, outlined recommendations and best practices for the catheter ablation procedure. The 2019 document — compiled by HRS,the European Heart Rhythm Association (EHRA), the Asia Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS) — is a complete and comprehensive update of the 2009 EHRA/HRS statement and is intended to supplement the 2017 AHA/ACC/HRS Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.

"Over the last decade, the field of electrophysiology has undergone rapid progress and the number of ablations performed across the globe has grown significantly," said document chair Edmond Cronin, MB, BCh, BAO, FHRS, CCDS, CEPS-A, Hartford Hospital. "From new literature and clinical trials to technology innovations and improved understanding of ventricular arrhythmias, our organizations recognized the overdue need for an updated consensus statement to reflect the vast advancements."

The writing group, comprised of 38 experts from international organizations, addresses the important issue of catheter ablation of VAs. The consensus statement uses a systematic review designed specifically for the document as part of HRS’s efforts to adopt the rigorous methodology required for guideline development, and was led by an experienced evidenced-based practice committee. Where possible, the recommendations are evidence-based with the intention to set reasonable standards that can be applicable worldwide. The group also addresses the need for appropriate physician training and identified patient suitability for the procedure in the clinical setting.

Specifically, the document includes detailed findings within the following topic areas:

  • Definitions, Mechanisms and History of Ventricular Arrhythmia Ablation;
  • Clinical Evaluation;
  • Indications for Catheter Ablation;
  • Procedural Planning;
  • Intraprocedural Patient Care;
  • Electrophysiological Testing;
  • Mapping and Imaging Techniques;
  • Mapping and Ablation;
  • Postprocedural Care;
  • Training and Institutional Requirements and Competencies; and
  • Future Directions

"The purpose of this much-needed document is to serve as an updated resource guide and comprehensive review of the field for clinicians around the world who are working to improve the care of patients undergoing ablation for ventricular arrhythmias," said document vice-chair Frank Bogun, M.D., University of Michigan. "With knowledge gained from this review, we recognize that moving forward, further research is needed to identify optimal methods of arrhythmia suppression and to understand the influencers of each method on arrhythmia outcomes."

The expert consensus statement on catheter ablation of VAs was written in collaboration with and endorsed by the American College of Cardiology (ACC), the American Heart Association (AHA), the Japanese Heart Rhythm Society (JHRS), the Pediatric and Congenital Electrophysiology Society (PACES) and the Sociedade Brasileira de Arritmias Cardíacas (SOBRAC). It was also endorsed by the Canadian Heart Rhythm Society (CHRS).

The final decisions regarding patient care should be made by healthcare providers and their patients. The organizations also strongly encourage additional patient-centered, prospective and randomized trials to move the field forward to promote patient health and minimize confounding biases.

The full document was published in the online edition of HeartRhythm, the official journal of the Heart Rhythm Society; EP Europace, a journal of the European Society of Cardiology; and the Journal of Arrhythmia, the official journal of the Japanese Heart Rhythm Society and the Asia Pacific Heart Rhythm Society.

For more information: www.heartrhythmjournal.com

Related Content

Noninvasive Radioablation Offers Long-term Benefits to High-risk Heart Arrhythmia Patients
News | Ablation Systems | September 17, 2019
September 17, 2019 — Treating high-risk heart patients with a single, high dose of radiation therapy can dramatically
Biosense Webster Announces Initial Results From First-in-Human QDOT-FAST Study
News | Ablation Systems | May 16, 2019
Johnson & Johnson Medical Devices Companies announced that Biosense Webster, Inc.’s QDot Micro catheter...
CardioFocus Announces Results From HeartLight X3 Ablation System Pivotal Study
News | Ablation Systems | May 16, 2019
CardioFocus Inc. announced the presentation of results from its pivotal confirmatory study evaluating the HeartLight X3...
Netherlands Hospital to Install State-of-the-Art MRI Ablation Center
News | Ablation Systems | May 13, 2019
Imricor announced the signing of a commercial agreement with the Haga Hospital in The Hague, Netherlands to outfit a...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Ablation Systems | May 10, 2019 | Dave Fornell, Editor
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve
Ablation Reduces Risk of Dementia in Patients With AFib and Carotid Artery Disease
News | Ablation Systems | May 08, 2019
Even though many medical practitioners may opt not to perform procedures on higher-risk patients, new research finds it...
CardioFocus Announces European CE Mark Approval Of HeartLight X3 System
News | Ablation Systems | April 16, 2019
CardioFocus Inc. announced the European CE Mark approval of the HeartLight X3 Endoscopic Ablation System.
First Patient Treated With QDot Micro Ablation Catheter
News | Ablation Systems | February 04, 2019
Biosense Webster has enrolled and treated the first patient in its U.S. Investigational Device Exemption (IDE) study...
FDA Approves TactiCath Contact Force Ablation Catheter, Sensor Enabled
Technology | Ablation Systems | January 21, 2019
Abbott announced U.S. Food and Drug Administration (FDA) approval of the TactiCath Contact Force Ablation Catheter,...
First Patient Treated in STELLAR Atrial Fibrillation IDE Study
News | Ablation Systems | November 30, 2018
Johnson & Johnson Medical Devices Companies announced that Biosense Webster Inc. has enrolled and treated the first...
Overlay Init